AARD — Aardvark Therapeutics Cashflow Statement
0.000.00%
- $172.05m
- $96.01m
- 25
- 26
- 38
- 19
Annual cashflow statement for Aardvark Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|
Period Length: | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K |
Standards: | USG | USG | USG |
Status: | Final | Final | Final |
Net Income/Starting Line | -13.6 | -7.21 | -20.6 |
Depreciation | |||
Non-Cash Items | 4.22 | 1.37 | 0.677 |
Unusual Items | |||
Other Non-Cash Items | |||
Changes in Working Capital | -1.31 | -0.081 | 1.57 |
Change in Prepaid Expenses | |||
Change in Accounts Payable | |||
Change in Accrued Expenses | |||
Cash from Operating Activities | -10.5 | -5.82 | -18.1 |
Capital Expenditures | — | — | -0.109 |
Purchase of Fixed Assets | |||
Other Investing Cash Flow Items | -1 | 0 | -11.9 |
Purchase of Investments | |||
Other Investing Cash Flow | |||
Cash from Investing Activities | -1 | 0 | -12 |
Financing Cash Flow Items | — | — | -3.34 |
Other Financing Cash Flow | |||
Net Issuance / Retirement of Stock | |||
Cash from Financing Activities | 0.225 | 0 | 82 |
Beginning Cash Balance | |||
Ending Cash Balance | |||
Net Change in Cash | -11.3 | -5.82 | 51.9 |